Daily Roundup

CAF.ASX SPR.ASX NYR.ASX PLY.ASX AD8.ASX

Centrepoint Alliance Reports Strong FY25 Results

Centrepoint Alliance Limited (ASX: CAF), a leading provider of financial advice and services, has reported its unaudited financial results and operational highlights for FY25. The company achieved strong financial performance, exceeding earnings guidance with expected normalised EBITDA of $10.6m, up $1.5m (+16%) on FY24. Expected Gross Revenue was $326.0m, up $38m (+13%) on FY24, while Expected Net Revenue (Gross Profit) was $40.9m, up $4.8m (+13%) on FY24. Expected NPBT was $7.3m, up $1.7m (+30%) on FY24.

The company continued its market leading growth in the licensee business, with a net growth of 22 authorised representatives ('ARs') for the year, bringing the total to 573 advisers operating under CAF licenses. Funds under management in managed accounts grew from $303m to $423m, up 40%, driven by the iQ Portfolios available on 5 investment and superannuation platforms. The IconiQ Superannuation and Investment platform was launched in December 2024 and is in the early stages of commercialisation, with a focus on onboarding advisers, building out the managed account offering, and completing integrations with adviser software applications. The company also completed the acquisition of Brighter Super's advice review book in June 2025, with 3 advisers transitioning to Financial Advice Matters ('FAM'), increasing the total number of employed advisers to 22.

Court Approves Scheme for Spartan Resources

Spartan Resources Limited (ASX: SPR) has announced that the Supreme Court of Western Australia has approved the scheme of arrangement for Ramelius Resources Limited (ASX: RMS) to acquire all of the issued shares of Spartan. Under the terms of the scheme, Spartan shareholders will receive $0.25 cash and 0.6957 new Ramelius shares per Spartan share. The scheme is expected to be implemented on 31 July 2025, with Spartan shares to be suspended from trading on the ASX after the close of trading on 22 July 2025.

Final Phase I Clinical Trial Patients Dosed and Discharged

Nyrada Inc, a clinical-stage drug discovery and development company, has announced the completion of dosing for all participants in the Phase I clinical trial of its lead candidate Xolatryp. The final cohort of participants have now been dosed and discharged from the trial site, marking a significant milestone in the development of Xolatryp. Throughout the trial, no safety signals, dose-limiting toxicities, or unexpected side effects have been observed. A full safety blood analysis, including pharmacokinetic assessment, will now be reviewed by the trial's Safety Review Committee. Once this data is available, the final clinical study report will be prepared in the coming months.

PlaySide Studios reports unaudited FY25 results

PlaySide Studios has reported its unaudited financial results for the year ended 30 June 2025. Revenue for the period was $48.5-49.0 million, slightly lower than the previous guidance of $50-54 million. The company reported an EBITDA loss (including $1.6 million of restructuring costs) of $7.2-7.7 million, within the previous guidance range of a $6-10 million loss. The cash balance at 30 June was $13.4-13.6 million, also within the previous guidance range of $10-15 million.

Audinate Completes Acquisition of Iris Studio Inc

Audinate Group Limited (ASX:AD8) has completed the acquisition of Iris Studio Inc, a US-based leader in AI-powered, cloud-based camera control technology, for total consideration of up to US$28 million. The acquisition of Iris significantly enhances Audinate's position in video and aligns closely with Audinate's broader vision for interoperable control and management of AV-over-IP solutions across a wide range of audio-visual devices.